PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of annrheumdAnnals of the Rheumatic DiseasesCurrent TOCInstructions for authors
 
Ann Rheum Dis. Dec 2003; 62(12): 1168–1177.
PMCID: PMC1754401
Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study
L B A van de Putte, R Rau, F Breedveld, J Kalden, M Malaise, P L C M van Riel, M Schattenkirchner, P Emery, G Burmester, H Zeidler, H Moutsopoulos, K Beck, and H Kupper
University Hospital Nijmegen, Nijmegen, The Netherlands.
Objectives: To evaluate efficacy, dose response, safety, and tolerability of adalimumab (D2E7) in disease modifying antirheumatic drug (DMARD) refractory patients with longstanding, active rheumatoid arthritis (RA).
Methods: During a 12 week, double blind, placebo controlled study, 284 patients were randomly allocated to receive weekly subcutaneous injections of adalimumab 20 mg (n = 72), 40 mg (n = 70), or 80 mg (n = 72) or placebo (n = 70) without concomitant DMARDs.
Results: Adalimumab significantly improved the signs and symptoms of RA for all efficacy measures. ACR20 responses with adalimumab were significant at each assessment versus placebo (p[less-than-or-eq, slant]0.01). Additionally, ACR responses with adalimumab were achieved more rapidly than with placebo, with 82/115 (71%) of the ultimate ACR20 response rate to adalimumab treatment achieved at week 2. At week 12, for adalimumab 20, 40, and 80 mg, ACR20 response rates were 50.7%, 57.1%, and 54.2%, respectively, versus 10.0% for placebo (p[less-than-or-eq, slant]0.001 for all comparisons); ACR50 rates were 23.9%, 27.1%, and 19.4%, respectively, versus 1.4% for placebo (p[less-than-or-eq, slant]0.001 for all comparisons); and ACR70 rates were 11.3%, 10.0%, and 8.3%, respectively, versus 0.0% for placebo (p[less-than-or-eq, slant]0.05 for all comparisons). All adalimumab doses significantly improved all ACR core criteria at all assessments. The 40 mg and 80 mg doses provided similar benefit. Adalimumab at all doses was generally well tolerated, with only mild or moderate adverse events. Completion rates were 87% for adalimumab and 67% for placebo.
Conclusions: Adalimumab given as monotreatment to patients with longstanding, severe RA refractory to traditional DMARDs produced a rapid, sustained response and was safe and well tolerated, with no dose limiting side effects.
Figure 1
Figure 1
Disposition of patients.
Figure 2
Figure 2
Time course of American College of Rheumatology responses. (A) ACR20 response; (B) ACR50 response; (C) ACR70 response. Student's paired t test for paired observations: *p = 0.01 v baseline; †p = 0.01 v baseline; ‡p = 0.05 v v baseline. (more ...)
Figure 3
Figure 3
Improvement in American College of Rheumatology core criteria at 12 weeks with adalimumab 40 mg. Student's t test for paired observations: p = 0.001 v baseline.
Articles from Annals of the Rheumatic Diseases are provided here courtesy of
BMJ Group